OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CLNYSE$85.9767

COLGATE PALMOLIVE CO

Personal ProductsVerified

Colgate-Palmolive's capital structure is characterized by a high debt-to-equity ratio of 147.89, indicating a significant reliance on debt financing. The company's liquidity position is marked by a current ratio of 0.83, which is below 1, suggesting that its current liabilities exceed its current assets. This is further supported by the risk assessment, which identifies liquidity as a high risk. In terms of profitability, Colgate-Palmolive's return on equity (ROE) of 39.48% is notably high, indicating efficient use of shareholders' equity to generate profits. However, the return on assets (ROA) of 13.06% is relatively modest, suggesting that the company may not be utilizing its assets as effectively as it could be. The company's revenue is distributed across five geographic segments: North America, Latin America, Europe, Asia Pacific, and Africa/Eurasia. The Oral, Personal, and Home Care segments are managed geographically, while the Pet Nutrition segment is a separate business unit. The company's exposure to North America is significant, but the exact concentration of revenue across these segments is not disclosed. Colgate-Palmolive's growth trajectory is influenced by its strategic initiatives, including innovation and omni-channel demand generation. The company's outlook for the current fiscal year indicates a focus on leveraging its global brand reach and supply chain resilience. However, the exact numeric deltas for revenue growth are not provided in the input data. Risk factors for Colgate-Palmolive include high liquidity risk due to current liabilities exceeding current assets and a high debt-to-equity ratio. The company's risk assessment also flags the potential for dilution as low, with no immediate pressure for additional equity issuance. The adjustments applied in the custom valuations suggest that the company's financial position is being closely monitored for any necessary corrections. Recent events, as detailed in the filings, include the company's assessment of new accounting guidance and its impact on financial reporting. The company is also involved in various legal matters, including the Brazilian matters and talcum powder litigation, which could affect its financial performance and reputation.

30-day price · CL+6.59 (+7.8%)
Low$81.79High$91.52Close$90.61As of22 May, 00:00 UTC
Profile
CompanyCOLGATE PALMOLIVE CO
ExchangeNYSE
TickerCL
CIK0000021665
SICPerfumes, Cosmetics & Other Toilet Preparations
SectorConsumer Non-Cyclicals
BusinessPersonal & Household Products & Services
Industry groupPersonal & Household Products & Services
IndustryPersonal Products
AI analysis

Business. Colgate-Palmolive Company operates in the Personal & Household Products & Services industry, focusing on Oral Care, Personal Care, Home Care, and Pet Nutrition. The company generates revenue through the sale of consumer products under well-known brands such as Colgate, Palmolive, and Hill's Science Diet to a variety of traditional and e-commerce retailers, wholesalers, distributors, dentists, and skin health professionals.

Classification. Colgate-Palmolive is classified under the Personal Products industry within the Consumer Non-Cyclicals economic sector, with a classification confidence of 0.92.

Colgate-Palmolive's capital structure is characterized by a high debt-to-equity ratio of 147.89, indicating a significant reliance on debt financing. The company's liquidity position is marked by a current ratio of 0.83, which is below 1, suggesting that its current liabilities exceed its current assets. This is further supported by the risk assessment, which identifies liquidity as a high risk. In terms of profitability, Colgate-Palmolive's return on equity (ROE) of 39.48% is notably high, indicating efficient use of shareholders' equity to generate profits. However, the return on assets (ROA) of 13.06% is relatively modest, suggesting that the company may not be utilizing its assets as effectively as it could be. The company's revenue is distributed across five geographic segments: North America, Latin America, Europe, Asia Pacific, and Africa/Eurasia. The Oral, Personal, and Home Care segments are managed geographically, while the Pet Nutrition segment is a separate business unit. The company's exposure to North America is significant, but the exact concentration of revenue across these segments is not disclosed. Colgate-Palmolive's growth trajectory is influenced by its strategic initiatives, including innovation and omni-channel demand generation. The company's outlook for the current fiscal year indicates a focus on leveraging its global brand reach and supply chain resilience. However, the exact numeric deltas for revenue growth are not provided in the input data. Risk factors for Colgate-Palmolive include high liquidity risk due to current liabilities exceeding current assets and a high debt-to-equity ratio. The company's risk assessment also flags the potential for dilution as low, with no immediate pressure for additional equity issuance. The adjustments applied in the custom valuations suggest that the company's financial position is being closely monitored for any necessary corrections. Recent events, as detailed in the filings, include the company's assessment of new accounting guidance and its impact on financial reporting. The company is also involved in various legal matters, including the Brazilian matters and talcum powder litigation, which could affect its financial performance and reputation.
Key takeaways
  • Colgate-Palmolive has a high debt-to-equity ratio, indicating a significant reliance on debt financing.
  • The company's return on equity is high, but its return on assets is relatively modest.
  • The company's liquidity position is a high risk, with current liabilities exceeding current assets.
  • Colgate-Palmolive's growth is influenced by its strategic initiatives and global brand reach.
  • The company is involved in legal matters that could impact its financial performance and reputation.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "The company's margin outlook is driven by its focus on innovation and cost management initiatives.",
Financial snapshot
PeriodFY2025
CurrencyUSD
Revenue$20.38B
Gross profit$12.25B
Operating income$3.31B
Net income$2.13B
R&D$366.0M
SG&A
D&A$630.0M
SBC$155.0M
Operating cash flow$4.20B
CapEx
Free cash flow
Total assets$16.33B
Total liabilities$15.96B
Total equity$54.0M
Cash & equivalents$1.29B
Long-term debt$6.87B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY2025$20.38B$3.31B$2.13B
FY2024$20.10B$4.27B$2.89B
FY2025$20.10B$4.27B$2.89B
FY2023$19.46B$3.98B$2.30B
FY2024$19.46B$3.98B$2.30B
PeriodGross %Op %Net %FCF %
FY2025
FY2024
FY2025
FY2023
FY2024
PeriodAssetsEquityCashDebt
FY2025$16.33B$54.0M$1.29B
FY2024$16.05B$212.0M$1.10B
FY2025$16.05B$212.0M$1.10B
FY2023$16.39B$609.0M$966.0M
FY2024$16.39B$609.0M$966.0M
PeriodOCFCapExFCFSBC
FY2025$4.20B$155.0M
FY2024$4.11B$135.0M
FY2025$4.11B$135.0M
FY2023$3.75B$122.0M
FY2024$3.75B$122.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
Q3 2025$15.15B$3.21B$2.17B
Q2 2025$10.02B$2.16B$1.43B
Q1 2025$4.91B$1.08B$690.0M
Q1 2025
PeriodGross %Op %Net %FCF %
Q3 2025
Q2 2025
Q1 2025
Q1 2025
PeriodAssetsEquityCashDebt
Q3 2025$17.51B$856.0M$1.28B
Q2 2025$17.47B$702.0M$1.22B
Q1 2025$16.65B$363.0M$1.11B
Q1 2025$16.05B$212.0M$1.10B
PeriodOCFCapExFCFSBC
Q3 2025$2.75B$127.0M
Q2 2025$1.48B$55.0M
Q1 2025$600.0M$23.0M
Q1 2025
Valuation
Market price$85.97
Market cap$69.73B
Enterprise value$76.32B
P/E32.7
Reported non-GAAP P/E
EV/Revenue3.7
EV/Op income23.1
EV/OCF18.2
P/B
P/Tangible book
Tangible book-$4.29B
Net cash-$6.59B
Current ratio0.8
Debt/Equity147.9
ROA13.1%
ROE39.5%
Cash conversion2.0%
CapEx/Revenue
SBC/Revenue0.8%
Asset intensity0.3
Dilution ratio1.2%
Risk assessment
Dilution riskLow
Liquidity riskHigh
  • Current liabilities exceed current assets.
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Personal Products · cohort 225 companies
MetricCLActivity
Op margin16.2%16.2% medp25 16.2% · p75 16.2%top quartile
Net margin10.5%10.5% medp25 10.5% · p75 10.5%bottom quartile
Gross margin60.1%60.1% medp25 60.1% · p75 60.1%top quartile
R&D / revenue1.8%1.8% medp25 1.8% · p75 1.8%top quartile
CapEx / revenue-2.3% medp25 -4.4% · p75 -1.1%
Debt / equity14789.0%12724.1% medp25 12724.1% · p75 12724.1%top quartile
Observations
IR observations
Mean price target94.32 USD
Median price target98.00 USD
High price target105.00 USD
Low price target75.00 USD
Mean recommendation2.41 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count11.00
Hold count8.00
Sell count0.00
Strong-sell count1.00
Mean EPS estimate3.83 USD
Last actual EPS3.69 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Market quoteclose USD 85.97 · shares 0.81B diluted
no public URL
2026-05-01 04:25 UTC#23243f3d
Source: analysis-pipeline (hybrid)Generated: 2026-05-01 04:27 UTCJob: 56db10d3